These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Discovery of dihydroquinoxalinone acetamides containing bicyclic amines as potent Bradykinin B1 receptor antagonists. Chen JJ; Qian W; Biswas K; Viswanadhan VN; Askew BC; Hitchcock S; Hungate RW; Arik L; Johnson E Bioorg Med Chem Lett; 2008 Aug; 18(16):4477-81. PubMed ID: 18674903 [TBL] [Abstract][Full Text] [Related]
5. Aspartic acid scaffold in bradykinin B1 antagonists. Huszár J; Timár Z; Bogár F; Penke B; Kiss R; Szalai KK; Schmidt E; Papp A; Keseru G J Pept Sci; 2009 Jun; 15(6):423-34. PubMed ID: 19378355 [TBL] [Abstract][Full Text] [Related]
6. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore. Axe FU; Bembenek SD; Szalma S J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444 [TBL] [Abstract][Full Text] [Related]
7. Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites. Fowler CB; Pogozheva ID; LeVine H; Mosberg HI Biochemistry; 2004 Jul; 43(27):8700-10. PubMed ID: 15236578 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist. Ransom RW; Harrell CM; Reiss DR; Murphy KL; Chang RS; Hess JF; Miller PJ; O'Malley SS; Hey PJ; Kunapuli P; Su DS; Markowitz MK; Wallace MA; Raab CE; Jones AN; Dean DC; Pettibone DJ; Freidinger RM; Bock MG Eur J Pharmacol; 2004 Sep; 499(1-2):77-84. PubMed ID: 15363953 [TBL] [Abstract][Full Text] [Related]
9. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Castonguay LA; Weng Y; Adolfsen W; Di Salvo J; Kilburn R; Caldwell CG; Daugherty BL; Finke PE; Hale JJ; Lynch CL; Mills SG; MacCoss M; Springer MS; DeMartino JA Biochemistry; 2003 Feb; 42(6):1544-50. PubMed ID: 12578367 [TBL] [Abstract][Full Text] [Related]
10. Molecular modeling of A1 and A2A adenosine receptors: comparison of rhodopsin- and beta2-adrenergic-based homology models through the docking studies. Yuzlenko O; Kieć-Kononowicz K J Comput Chem; 2009 Jan; 30(1):14-32. PubMed ID: 18496794 [TBL] [Abstract][Full Text] [Related]
11. 3D model for TM region of the AT-1 receptor in complex with angiotensin II independently validated by site-directed mutagenesis data. Nikiforovich GV; Marshall GR Biochem Biophys Res Commun; 2001 Sep; 286(5):1204-11. PubMed ID: 11527428 [TBL] [Abstract][Full Text] [Related]
12. Insight into the binding mode for cyclopentapeptide antagonists of the CXCR4 receptor. Våbenø J; Nikiforovich GV; Marshall GR Chem Biol Drug Des; 2006 May; 67(5):346-54. PubMed ID: 16784459 [TBL] [Abstract][Full Text] [Related]
13. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. Berkhout TA; Blaney FE; Bridges AM; Cooper DG; Forbes IT; Gribble AD; Groot PH; Hardy A; Ife RJ; Kaur R; Moores KE; Shillito H; Willetts J; Witherington J J Med Chem; 2003 Sep; 46(19):4070-86. PubMed ID: 12954060 [TBL] [Abstract][Full Text] [Related]
14. Development of a 3D model for the human cannabinoid CB1 receptor. Salo OM; Lahtela-Kakkonen M; Gynther J; Järvinen T; Poso A J Med Chem; 2004 Jun; 47(12):3048-57. PubMed ID: 15163186 [TBL] [Abstract][Full Text] [Related]
15. Molecular modeling studies on the human neuropeptide S receptor and its antagonists. Dal Ben D; Antonini I; Buccioni M; Lambertucci C; Marucci G; Vittori S; Volpini R; Cristalli G ChemMedChem; 2010 Mar; 5(3):371-83. PubMed ID: 20087922 [TBL] [Abstract][Full Text] [Related]
16. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model. Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194 [TBL] [Abstract][Full Text] [Related]
17. Ligand binding to the human MT2 melatonin receptor: the role of residues in transmembrane domains 3, 6, and 7. Mazna P; Berka K; Jelinkova I; Balik A; Svoboda P; Obsilova V; Obsil T; Teisinger J Biochem Biophys Res Commun; 2005 Jul; 332(3):726-34. PubMed ID: 15913560 [TBL] [Abstract][Full Text] [Related]
18. Binding crevice for TT-232 in a homology model of type 1 somatostatin receptor. Simon A; Czajlik A; Perczel A; Kéri G; Nyikos L; Emri Z; Kardos J Biochem Biophys Res Commun; 2004 Apr; 316(4):1059-64. PubMed ID: 15044092 [TBL] [Abstract][Full Text] [Related]
19. New insights into the stereochemical requirements of the bradykinin B1 receptor antagonists binding. Lupala CS; Gomez-Gutierrez P; Perez JJ J Mol Graph Model; 2016 Jul; 68():184-196. PubMed ID: 27469392 [TBL] [Abstract][Full Text] [Related]
20. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists. Dastmalchi S; Hamzeh-Mivehroud M; Ghafourian T; Hamzeiy H J Mol Graph Model; 2008 Jan; 26(5):834-44. PubMed ID: 17561422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]